ImaRx Pharmaceutical, Inc.
ImaRx Pharmaceutical, Inc.
Sale of ImaRx Pharmaceuticals, Inc. to DuPont for $44 Million in DuPont Common Stock. Sale included the rights to the lipid based imaging patent for cardiovascular pharmaceuticals only on a world-wide basis.